Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response
Ping Zhang(Inner Mongolia Agricultural University), Gareth L. Bond(Ludwig Cancer Research), Lukasz F. Grochola(Kantonsspital Winterthur), P. Richter(Ludwig Cancer Research), Rick Jansen(Amsterdam Neuroscience), Svanhild Nornes(Ludwig Cancer Research), Sarah De Val(British Heart Foundation), Isaac Kitchen-Smith(Ludwig Cancer Research), Clare Turnbull(Institute of Cancer Research), Katherine A. Brown(Imperial College London), Natasha Sahgal(University of Oxford), Xuting Wang(National Institute of Environmental Health Sciences), Meghana S. Pagadala(University of California San Diego), Douglas A. Bell(Peralta Community College District), Joanna Selfe(Institute of Cancer Research), Ian Tomlinson(University of Oxford), Jorge Zerón-Medina(Institute of Cancer Research), Mirvat Surakhy(Ludwig Cancer Research), David Sims(Institute of Cancer Research), Andrew Protheroe(University of Oxford), Sarah P. Blagden(Churchill Hospital), Yanyan Jiang(CRUK/MRC Oxford Institute for Radiation Oncology), Siddhartha Kar(University of Cambridge), Val Millar(Nuffield Orthopaedic Centre), Chey Loveday(Institute of Cancer Research), Samantha Moore(University of Bristol), Lingyun Xiong(Ludwig Cancer Research), Enric Domingo(Universitätsklinikum Erlangen), Elisabeth E. Bond(Ludwig Cancer Research), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Marsha D. Wallace(Ludwig Cancer Research), Tim Maughan(University of Liverpool), Giovanni Stracquadanio(Ludwig Cancer Research), Daniel Ebner, Hannah Carter(University of California San Diego), Janet Shipley(Institute of Cancer Research), Anderson J. Ryan(University of Oxford), Claire Palles(University of Oxford)
Cited by 49
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k